At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 40 enrolled
Drug / intervention
VACV tablets (Adults or pediatrics) or granules (pediatrics)drug
Likely dose
VACV tablets (Adults or pediatrics) or granules (pediatrics) 556 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-label Study to Evaluate Preventive Efficacy for Herpes Simplex Virus Infection and Safety of 256U87 (Valaciclovir Hydrochloride) in Adult and Pediatric Hematopoietic Stem Cell Transplantation Patients
In Brief
A Phase 3 clinical trial evaluating VACV tablets (Adults or pediatrics) or granules (pediatrics) for Herpes Simplex. Completed, enrolled 40 participants across 11 sites.
Detailed Summary
The purpose of this study is to evaluate the preventive efficacy for HSV infection and safety of valaciclovir (VACV) in the adult and pediatric HSCT patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Simplex
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2012
First PostedMay 2012
Primary CompletionMay 2013
Study CompletionMay 2013
TodayJul 2026
First PostedMay 21, 2012
Enrollment StartMay 7, 2012
Primary CompletionMay 1, 2013
Study CompletionMay 24, 2013
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 14.1 years ago
Interventions
VACV tablets (Adults or pediatrics) or granules (pediatrics)drug
A white to slightly yellowish white film coated tablet contains 556 mg of valaciclovir hydrochloride (500 mg of valaciclovir)). VACV granules have no or slightly specific odor.